Drug class
Antiretroviral - Fusion Inhibitors
Antiretroviral fusion inhibitors are a specialized class of entry-inhibiting medications indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Read more about Antiretroviral - Fusion Inhibitors
0 drugs in this class 0 manufacturers
Drugs in Antiretroviral - Fusion Inhibitors
No drugs are available
This class does not currently contain public drugs.
Antiretroviral fusion inhibitors are a specialized class of entry-inhibiting medications indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
They function by binding to the heptad repeat region of the viral envelope glycoprotein gp41, thereby preventing the conformational changes necessary for the viral envelope to fuse with the host CD4 T-cell membrane.
By blocking viral entry into target immune cells, these agents suppress viral replication.
In clinical practice, they are typically utilized alongside an optimized background antiretroviral regimen in treatment-experienced individuals harboring drug-resistant strains of HIV-1.
-
fda.gov
Antiretroviral fusion inhibitors are a specialized class of entry-inhibiting medications indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection They function by binding to the heptad repeat region of the viral envelope glycoprotein gp41, thereby preventing the conformational changes necessary for the viral envelope to fuse with the host CD4 T-cell membrane
-
nih.gov
Antiretroviral fusion inhibitors are a specialized class of entry-inhibiting medications indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection In clinical practice, they are typically utilized alongside an optimized background antiretroviral regimen in treatment-experienced individuals harboring drug-resistant strains of HIV-1
-
hiv.gov
They function by binding to the heptad repeat region of the viral envelope glycoprotein gp41, thereby preventing the conformational changes necessary for the viral envelope to fuse with the host CD4 T-cell membrane
-
nih.gov
They function by binding to the heptad repeat region of the viral envelope glycoprotein gp41, thereby preventing the conformational changes necessary for the viral envelope to fuse with the host CD4 T-cell membrane
-
nih.gov
By blocking viral entry into target immune cells, these agents suppress viral replication
-
nih.gov
By blocking viral entry into target immune cells, these agents suppress viral replication
-
nih.gov
In clinical practice, they are typically utilized alongside an optimized background antiretroviral regimen in treatment-experienced individuals harboring drug-resistant strains of HIV-1
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.